Health
New gene therapy could treat dominant optic atrophy – Drug Target Review
Researchers have found that an OPA1-targeted gene therapy can treat dominant optic atrophy in pre-clinical trials.
Posted: 27 November 2020 | Victoria Rees (Drug Target Review) | No comments yet
Researchers have found that an OPA1-targeted gene therapy can treat dominant optic atrophy in pre-clinical trials.
Scientists have developed a new gene therapy approach that they say offers promise for one day treating an eye disease that leads to a progressive loss of vision and affects thousands of people across the globe. The study was led by researchers at Trinity College Dublin, Ireland.
A fluorescent microscope…
-
Noosa News24 hours agoInside the final hours before Australian lawyer Christopher Saines died in Thai massage parlour
-
General21 hours agoGerman backpacker Carolina Wilga found alive in WA’s outback
-
Business24 hours agoHow $1,000 a month in this ASX ETF could turn into $500,000
-
Noosa News24 hours agoGrow it local | Noosa Today